Fundacio Assistencial De Mutua De Terrassa Fpc
- Address
- lock Available on a paid plan
Neurology and Neurodegenerative Disease Research
At Fundacio Assistencial De Mutua De Terrassa Fpc, clinical research in nervous system diseases focuses strongly on Alzheimer’s disease, with studies in early, mild, and dementia stages. These trials are designed to test new treatment options, explore symptom control, and better understand how the disease progresses over time.
- Early Alzheimer’s disease with biomarkers of inflammation
- Mild Alzheimer’s disease
- Treatment of Alzheimer’s disease dementia
- Evaluating novel therapies aimed at slowing cognitive decline
The site’s Neurology department also contributes to broader efforts in improving diagnosis and treatment response for patients living with progressive brain disorders.
Stroke and Atrial Fibrillation Studies
Research in cardiovascular diseases includes trials for acute ischemic stroke, high-risk transient ischemic attack, and atrial fibrillation. These studies aim to reduce the risk of future stroke and improve prevention strategies for patients who may not be able to use standard anticoagulation treatments.
- Preventing recurrent ischemic stroke after a recent event
- Lowering stroke risk in atrial fibrillation
- Testing safer approaches for patients unsuitable for oral anticoagulation
This area reflects a clear focus on improving long-term protection against serious thromboembolic complications.
Hematology and Blood Cancer Trials
The site is active in hemic and lymphatic diseases, with studies involving acute myeloid leukemia, myelodysplastic syndrome, follicular lymphoma, marginal zone lymphoma, and Waldenström’s macroglobulinemia. The research is centered on testing new cancer treatments and comparing their effectiveness in difficult-to-treat blood cancers.
- New treatment approaches for AML and IDH1-mutated AML
- Therapy comparisons in relapsed or refractory lymphoma
- Options for relapsed/refractory Waldenström’s macroglobulinemia
- Evaluating treatment safety and disease control in hematologic malignancies
These studies support progress in oncology by seeking better outcomes for patients with relapsed, resistant, or newly diagnosed blood cancers.
Solid Tumor Oncology Research
Within neoplasms, the trials at this site include early-stage breast cancer and advanced ovarian, tubal, or peritoneal cancer. The research aims to understand long-term outcomes after treatment and to evaluate strategies that may improve disease control and survival in women’s cancers.
- Long-term follow-up in early invasive breast cancer
- Treatment strategies for advanced ovarian and related gynecologic cancers
- Assessing relapse patterns and progression-free survival
These studies combine follow-up research with treatment evaluation to help refine care pathways in oncology.
Infectious Disease Research
The site also participates in studies on bacterial infections and mycoses, especially severe community-acquired bacterial pneumonia. This research is focused on improving recovery, testing adjunctive treatment options, and strengthening care for patients with serious respiratory infection.
- Severe community-acquired bacterial pneumonia
- Evaluating new supportive treatment approaches
- Measuring clinical recovery and safety outcomes
These trials contribute to better management of complex infections in a hospital setting.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 121 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 119 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1UCB Biopharma2active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fundacio Assistencial De Mutua De Terrassa Fpc
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease | Merck Sharp & Dohme LLC | Phase II | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 121 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lenalidomide | 6 | Unknown | 2018-11-15 | 2023-09-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
